Key result
Achieving trial-equivalent effectiveness with vitamin K antagonists in clinical practice could avoid 13.79 strokes per 100 patients over 5 years, triggering €1.75 million in lifetime cost savings.
Why the study?
What are the key components and drivers of health economic evaluations for antithrombotic treatments in patients with atrial fibrillation?
What are the key components and drivers of health economic evaluations for antithrombotic treatments in patients with atrial fibrillation?
Improving the clinical effectiveness of VKA therapy to match trial efficacy could yield substantial health and economic benefits by preventing strokes.
Answers are grounded in this paper and cite their sources.
May support optimizing VKA management in AF to avert strokes and costs; leaves open real-world validation.
Our objective is to summarize the key components of a health economic evaluation of antithrombotic treatments for stroke prevention in patients with atrial fibrillation (AF). The key drivers are the changes in cost and quality of life associated with: thromboembolic events; the antithrombotic drug and its management; and bleeding events. Data on costs and utilities associated with all three components are presented. In clinical trials, vitamin K antagonists (VKAs, e.g. warfarin) substantially reduce the risk of stroke in patients with AF. However, the high cost of stroke makes clinical effectiveness a key element in the economic evaluation of stroke prevention interventions. Clinical effectiveness is lower than efficacy in clinical trials because of the variable anticoagulant effect and significant underuse of VKA therapy. The pure cost implication of reduced clinical effectiveness is illustrated using published data to extrapolate from clinical trials to clinical practice. If VKA effectiveness equivalent to that seen in trials could be achieved, 13.79 strokes per 100 patients over 5 years could be avoided compared with the typical current treatment pattern. If we take the lifetime cost of stroke to be €126 797 (based on a USA estimate), preventing these additional strokes will trigger lifetime cost savings of €1.75 million. Health economic decision-making must balance these gains against the cost of drug and management of VKA therapy.
No takes yet. Share an insight, caveat, or question.
Miller et al. (2005) conducted a review in Atrial fibrillation. Vitamin K antagonists (e.g., warfarin) vs. Typical current treatment pattern was evaluated on Strokes avoided and lifetime cost savings. Achieving trial-equivalent effectiveness with vitamin K antagonists in clinical practice could avoid 13.79 strokes per 100 patients over 5 years, triggering €1.75 million in lifetime cost savings.
Synapse has enriched 10 related papers. Consider them for comparative context: